SRRA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Dec 1970 @ 19:00):

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs...

Stats
Today's Volume	0.00
Average Volume	651 457
Market Cap	0.00
EPS	$0 ( 2022-08-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.34
ATR14	$0.324 (0.59%)

Insider Trading

Date	Person	Action	Amount	type
2022-07-01	Vivo Opportunity, Llc	Sell	431 947	Common Stock
2022-07-01	Vivo Opportunity, Llc	Sell	75 749	Series A Warrants
2022-07-01	Orbimed Advisors Llc	Sell	226 704	Common Stock
2022-07-01	Orbimed Advisors Llc	Sell	170 437	Series A Warrants
2022-07-01	Ashiya Mona	Sell	226 704	Common Stock

INSIDER POWER
-97.51
Last 99 transactions
Buy: 4 604 902 \| Sell: 10 646 034

Volume Correlation

Long: 0.15 (neutral)

Short: -0.71 (moderate negative)

Signal:(77.923) Neutral

Sierra Oncology Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sierra Oncology Inc Correlation - Currency/Commodity

0.76
( moderate )

0.83
( strong )

-0.57
( weak negative )

0.87
( strong )

-0.65
( weak negative )

Sierra Oncology Inc Financials

Annual	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-7.14

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-7.14

FY	2020
Revenue:	$300 000
Gross Profit:	$0.00 (0.00 %)
EPS:	$-7.70

FY	2019
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-30.30

Financial Reports:

No articles found.

Sierra Oncology Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Sierra Oncology Inc

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.